



















Figure S1. Evaluation of topological properties of network. (A) node degree distribution, (B) average clustering coefficient, (C) stress centrality, (D) closeness centrality and (E) betweenness centrality measure.






Figure S2. Kaplan-Mayer curves showing the overall survival (expressed in percentage) in solid cancer patients, using PROGeneV2 online tool, in the case of high and low expression of HUB nodes reported by red and green curves, respectively.

Table S1. List of primer sequences

Gene	Sequence 5'→3'
ABL1	TGGAGATAACACTCTAAGCATAACTAAACCT (31) GATGTAGTTGCTTGGGACCCA (21)
DIO1	AGCTTACTCTGGCTTTGCCGA (21) TATTACCCGTCTTCTCGCCCA (21)
DIO2	CTTACTCTGGCTTTGCCGAGA (21) CAGGATGTTCCGCTTGACTCT (21)
DIO3	GGTAGTTTCCCCCGCTTGTTT (21) TTAGGTGCTGCTTTGAGGCC (21)
EP300	TCCTTTCCATACCGAACC (18) GGACAATACGCTCTGATACA (20)
FYN	ATGGAAACACAAAAGTAGCCATAAA (25) TCTGTGAGTAAGATTCCAAAAGACC (25)
GPX1	TTATGACCGACCCCAAGCTCA (21) ATGTCAATGGTCTGGAAGCGG (21)
GPX2	GGAGAATGAACCCAAGCGAA (20) CAGGTTTGTACAGCCAGTGAT (22)
GPX3	TCTCATCCCATGTCCACCATG (21) TGCATCCATTTGTGCCAGG (19)
GPX4	AGAGATCAAAGAGTTCGCCGC (21) TCTTCATCCACTTCCACAGCG (21)
GPX6	CAGAAACCCACCTCACATGA (21) TGCCATGACCTGAATGCACT (20)
MSRB1	AGCGGCTGTTGCTCCATAACT (21) ATTTCAGCATCACCCACCCTC (21)
MYC	TGAATTAGAATCTCGGGAGTGC (22) GAGTGAGACCCCATCTCAGAA (21)
PSMB2	AGAGGGCAGTGGAACCTCCTT (20) AGGTTGGCAGATTCAGGATG (20)
SELENOF	ATCGGAGGCATGCAGAGAGTT (21) TCTGCAATCAGGATCCAGCTG (21)
SELENOH	GGTGGTGGAAGAGTTGAAGAA (21) AGGGACACAAAGCTCAGCAT (20)
SELENOI	AAAGGCCAGGTTCCAGAA (19) CAATCCTGCTGCAGTCCAAGT (21)
SELENOK	AATCAATCATCTGCGTGGCC (20) TGGTCAGCCTTCCACTTCTTG (21)
SELENOM	TCACGCAGGACATTCCATTCT (21) CCTGCACTAGCGCATTGATCT (21)
SELENON	AGGCAGATGCTCATTGTTCCC (21)

	CCCCAAATCCAGATGCAGACT (21)
SELENOO	CGGTTGTGTTGCGTGTAGCTT (21) TGCACTCGAATGTCGTTTCCTC (21)
SELENOP	TAGGAGCTGATGCTGCCATTG (21) ATGTTCTCCTCTGCCCCGAAGT (21)
SELENOS	CAGCTGCTCGACTGAAAATGC (21) GCATGCTGTCCCACATTTCAA (21)
SELENOT	TCAATCCCACACCATCGATCA (21) ACAACGAGCCTGCCAAGAAAG (21)
SELENOV	GTGGATTTCGTCATTTCCCATG (21) TTTGAGTCTGACTGCCATCCC (21)
SELENOW	GTTTATTGTGGCGCTTGAGGC (21) CCATCACTTCAAAGAACCCGG (21)
SEPHS2	CGGCTCGCTTTTGTCTGAA (20) TCGCGGCTTGTC AATGATC (19)
SRPK2	GCAAAGGACAATGGTGAAGCTGAGG (25) CATCATCATCTTCATCGTCCAGTTGC (26)
TXNRD1	CACAATTGGAATCCACCCTGT (21) GGTTTGCAGTCTTGGAACA (20)
TXNRD2	AGGACATTGCTGGTCGAAGC (21) GGAATCCCCTGGAAAAACGTT (21)
TXNRD3	CCTTTCCCAGTTGCTAGTGC (20) GTGCTACACTCTGGGCAACA (20)
VCP	GCCTTGAATGAAGTAGGGTAT(21) GTTGGGTCTGTTGGTTGC (18)
β-actin	TCTGGCACCACACCTTCTACAATG (24) AGCACAGCCTGGATAGCAACG (21)